백혈구 성분채집술 시장 : 기회, 성장 동인, 산업 동향 분석 및 예측(2024-2032년)

The Leukapheresis Market was valued at approximately USD 281.8 million in 2023 and is expected to grow at a CAGR of 12.7% from 2024 to 2032. Leukapheresis is a specialized medical procedure that extracts and collects white blood cells (leukocytes) from the bloodstream. The process involves drawing blood, filtering it through a machine to isolate the leukocytes, and then returning the remaining blood components, such as red blood cells and platelets, back to the patient.

The rising incidence of blood cancer is a major factor driving market growth. The increasing need for effective treatments has boosted the demand for leukapheresis, which plays a crucial role in managing these conditions by removing abnormal white blood cells and improving patient outcomes. Moreover, innovations in leukapheresis devices and methodologies, alongside a growing focus on immunotherapy and cell-based therapies, are further supporting the market. Government policies and initiatives also contribute to market expansion by fostering technological advancements and improving access to care.

The overall Leukapheresis industry is segregated based on Product, Application, End-use, and Region.

By product, the leukapheresis market is divided into disposables and devices. The disposable segment, including leukapheresis sets and tubing, is projected to reach USD 502.6 million by 2032. Disposables help reduce the risk of cross-contamination, eliminate the need for sterilization processes, and simplify procedures, enhancing both safety and efficiency in medical settings.

By application, the market is categorized into therapeutic and research segments. The therapeutic segment, which accounted for USD 155.5 million in 2023, includes treatments for hematology disorders and autoimmune diseases. Leukapheresis allows for the targeted collection of specific white blood cells, improving the effectiveness of treatments like immunotherapy and stem cell transplantation. It also aids in managing autoimmune conditions by removing harmful antibodies and immune complexes from the bloodstream.

By end-use, the market is segmented into blood component providers and blood centers, academic and research institutes, pharmaceutical and biotechnology companies, and hospital and transfusion centers. Hospitals and transfusion centers are expected to reach USD 297.7 million by 2032, with leukapheresis enabling efficient collection and separation of leukocytes for various treatments, including cancer immunotherapy.

The U.S. leukapheresis market is anticipated to grow significantly, reaching USD 280.5 million by 2032, driven by advancements in technology and the growing need for cancer treatments.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising cases of blood cancer and related disorders
    • 3.2.1.2 Innovations in leukapheresis devices and their procedures
    • 3.2.1.3 Surge in R&D focus on cell-based therapies and immunotherapy
    • 3.2.1.4 Supportive government initiatives and policies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Expensive leukapheresis devices
    • 3.2.2.2 Shortage of trained professionals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pricing analysis
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Disposables
• 5.3 Devices
  • 5.3.1 Centrifugal devices
  • 5.3.2 Membrane separators
  • 5.3.3 Other devices

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Therapeutic
  • 6.2.1 Hematology disorders
  • 6.2.2 Autoimmune diseases
  • 6.2.3 Other therapeutic applications
• 6.3 Research
  • 6.3.1 Cancer research
  • 6.3.2 Immunology research
  • 6.3.3 Other research applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Blood component providers and blood centers
• 7.3 Academic and research institutes
• 7.4 Pharmaceutical and biotechnology companies
• 7.5 Hospital and transfusion centers

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Asahi Kasei Corporation
• 9.2 Beijing ZKSK Technology Co., Ltd.
• 9.3 Baxter International Inc.
• 9.4 Cardinal Health, Inc.
• 9.5 Fresenius SE and Co. KGaA
• 9.6 Guangzhou DaJi Medical Science and Technology Co., Ltd.
• 9.7 Haemonetics Corporation
• 9.8 Macopharma
• 9.9 Medica SPA
• 9.10 Miltenyi Biotec
• 9.11 Mitra Industries Private Limited
• 9.12 Nikkiso Co. Ltd.
• 9.13 Puriblood Medical Co. Ltd.
• 9.14 SB-Kawasumi Laboratories, Inc.
• 9.15 Terumo BCT, Inc.